Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion.

abstract：:Donor lymphocyte infusion (DLI) is a form of cellular immunotherapy which is known to be effective in preventing relapse in leukemia by inducing graft versus leukemia (GVL) effect. In hematopoietic stem cell transplantation (HSCT) for benign hematological conditions including primary immune deficiency, mixed chimerism...

journal_title：Bone marrow transplantation

authors： Swaminathan VV,Uppuluri R,Patel S,Sivashankaran M,Ravichandran N,Ramanan KM,Ramakrishnan B,Vaidhyanathan L,Raj R

更新日期：2019-11-01 00:00:00

abstract：:Reconstitution of the adaptive immune system following allogeneic hematopoietic stem cell transplantation is crucial for beneficial outcome and is affected by several factors, such as GvHD and graft source. The impact of these factors on immune reconstitution has been thoroughly investigated during the early phase aft...

journal_title：Bone marrow transplantation

authors： Gaballa A,Norberg A,Stikvoort A,Mattsson J,Sundberg B,Uzunel M,Remberger M,Uhlin M

更新日期：2018-01-01 00:00:00

abstract：:Four human fetuses were treated by transplantation of human fetal liver stem cells. Two of them had severe immunodeficiency disease and the two other ones had thalassemia major. Three of these in utero transplants were followed by engraftment. The three patients are now born: the first one is now very healthy thanks t...

journal_title：Bone marrow transplantation

authors： Touraine JL,Raudrant D,Rebaud A,Roncarolo MG,Laplace S,Gebuhrer L,Betuel H,Frappaz D,Freycon F,Zabot MT

更新日期：1992-01-01 00:00:00

abstract：:MHC Class II deficiency is a rare primary immunodeficiency disease characterized by absent HLA Class II expression resulting in CD4 lymphopenia, lack of Ag-specific responses and recurrent infection. Without successful allogeneic SCT, most children succumb to infection within the first decade of life. To date, alterna...

journal_title：Bone marrow transplantation

authors： Small TN,Qasim W,Friedrich W,Chiesa R,Bleesing JJ,Scurlock A,Veys P,Sparber-Sauer M

更新日期：2013-02-01 00:00:00

abstract：:Intermediate-dose salvage therapy is frequently given for relapsed and resistant lymphomas and is usually intensely myelosuppressive. In an attempt to reduce the haematological toxicity of miniBEAM, one of the commonly used salvage regimens, peripheral blood stem cell (PBSC) support was given to 21 consecutive patient...

journal_title：Bone marrow transplantation

authors： Fielding AK,Goldstone AH,Sullivan AM,Watts MJ,Jamieson E,Linch DC

更新日期：1996-09-01 00:00:00

abstract：:Intensive high-dose chemotherapy with peripheral blood progenitor cell (PBPC) transplantation is a common strategy for aggressive non-Hodgkin's lymphomas (NHL). A retrospective cost-effectiveness analysis of CD34+ cell dose was carried out. Between 1994 and 1998, 28 patients were included. Efficacy was measured by the...

journal_title：Bone marrow transplantation

authors： Limat S,Woronoff-Lemsi MC,Deconinck E,Racadot E,Jacquet M,Herve P,Cahn JY

更新日期：2000-05-01 00:00:00

abstract：:Posaconazole has been proven to be as effective as fluconazole in the prevention of invasive fungal infections (IFI) in allogeneic haematopoietic SCT patients with GVHD. We assessed, from the perspective of the Spanish National Health Service, the cost-effectiveness of posaconazole vs fluconazole in preventing IFI. A ...

journal_title：Bone marrow transplantation

authors： de la Cámara R,Jarque I,Sanz MA,Grau S,Casado MA,Sabater FJ,Carreras E

更新日期：2010-05-01 00:00:00

abstract：:Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 x 10(6) CD34 cells/kg (range 1.2-30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage co...

journal_title：Bone marrow transplantation

authors： Schiller G,Vescio R,Freytes C,Spitzer G,Lee M,Wu CH,Cao J,Lee JC,Lichtenstein A,Lill M,Berenson R,Berenson J

更新日期：1998-01-01 00:00:00

abstract：:This retrospective study from the Italian Association of Pediatric Hematology Oncology-Bone Marrow Transplant Group (AIEOP-TMO) reports the results of consolidation with high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with acute myeloid leukemia (AML) in first complet...

journal_title：Bone marrow transplantation

authors： Cesaro S,Meloni G,Messina C,Pillon M,Proglia A,Lanino E,Caniggia M,Bagnulo S,Pession A,Locatelli F,Italian Pediatric Group for Bone Marrow Transplantation.

更新日期：2001-07-01 00:00:00

abstract：:Historically, the mortality of patients admitted to the ICU after allogeneic stem cell transplantation (alloSCT) is high. Advancements in transplantation procedures, infectious monitoring and supportive care may have improved the outcome. This study aimed to determine short-term and long-term mortality after ICU admis...

journal_title：Bone marrow transplantation

authors： van der Heiden PLJ,Arbous MS,van Beers EJ,van den Bergh WM,le Cessie S,Demandt AMP,Eefting M,Hess C,Kusadasi N,Marijt WAF,van Mook WNKA,Müller MCA,Tuinman PR,van Vliet M,van Westerloo DJ,Blijlevens NMA,HEMA-ICU Study Grou

更新日期：2019-03-01 00:00:00

abstract：:Cyclosporin A (CsA) has been used clinically to induce graft-versus-host disease following autologous bone marrow transplantation in an attempt to destroy residual leukemia cells and reduce relapse. To analyze the antitumor potential of murine syngeneic graft-versus-host disease (SGVHD), C3H/HeN mice were lethally irr...

journal_title：Bone marrow transplantation

authors： Bryson JS,Jennings CD,Lowery DM,Carlson SL,Pflugh DL,Caywood BE,Kaplan AM

更新日期：1999-02-01 00:00:00

abstract：:Complex factors determine how physicians select between alternative therapies. We conducted a survey of 352 leukemia experts to determine consensus regarding optimal treatment for leukemia and to identify factors correlated with therapy decisions. The study evaluated both general treatment policies and recommendations...

journal_title：Bone marrow transplantation

authors： Atkinson KA,Horowitz MM,Sobocinski KA,Rimm AA,Bortin MM,Gale RP

更新日期：1992-01-01 00:00:00

abstract：:The bare lymphocyte syndrome is a combined immunodeficiency resulting from the lack of expression of either class I or class II HLA antigens at the cell surface. The main clinical manifestations are infections of the respiratory or the digestive tract. The immunodeficiency involves the absence of antibody formation an...

journal_title：Bone marrow transplantation

authors： Touraine JL,Marseglia GL,Betuel H,Souillet G,Gebuhrer L

更新日期：1992-01-01 00:00:00

abstract：:Certain leukemias have a high relapse risk even after allo-SCT, and GVHD prophylaxis with calcineurin inhibitors (CNIs) may interfere with a possible GVL effect. Therefore, we replaced CYA by sirolimus in patients with high relapse risk. In contrast to CNIs, sirolimus promotes the generation of regulatory T-cells and ...

journal_title：Bone marrow transplantation

authors： Schleuning M,Judith D,Jedlickova Z,Stübig T,Heshmat M,Baurmann H,Schwerdtfeger R

更新日期：2009-05-01 00:00:00

abstract：:The aim of this phase II study was to determine the feasibility of using two (tandem) courses of high-dose alkylating agents with bone marrow or peripheral blood progenitor cell support in women with stage IV breast cancer. Women with stage IV breast cancer who had achieved a CR or PR during conventional chemotherapy ...

journal_title：Bone marrow transplantation

authors： Bitran JD,Samuels B,Klein L,Hanauer S,Johnson L,Martinec J,Harris E,Kempler J,White W

更新日期：1996-02-01 00:00:00

abstract：:Among patients with myelodysplastic syndrome (MDS) undergoing hematopoietic cell transplantation (HCT), the impact of residual pretransplant cytogenetically abnormal cells on outcomes remains uncertain. We analyzed HCT outcomes by time of transplant disease variables, including (1) blast percentage, (2) percentage of ...

journal_title：Bone marrow transplantation

authors： Trottier BJ,Sachs Z,DeFor TE,Shune L,Dolan M,Weisdorf DJ,Ustun C,Warlick ED

更新日期：2016-02-01 00:00:00

abstract：:We conducted a controlled, double-blind study of parenteral glutamine supplementation in an unselected group of consecutive autologous transplant patients. Patients received 30 g of alanyl-glutamine dipeptide (Dipeptiven; Fresenius-Kabi, Bad Homburg, Germany) or glutamine-free amino acid solution i.v. from day +1 to d...

journal_title：Bone marrow transplantation

authors： Pytlík R,Benes P,Patorková M,Chocenská E,Gregora E,Procházka B,Kozák T

更新日期：2002-12-01 00:00:00

abstract：:Through two consecutive trials, a policy that considered allogeneic stem cell transplantation (SCT) from a sibling donor in second rather than first complete remission (CR) in selected younger patients with acute myeloid leukemia (AML) with t(8;21)/inv(16) (core binding factor (CBF) group) or a normal karyotype (NN gr...

journal_title：Bone marrow transplantation

authors： de Labarthe A,Pautas C,Thomas X,de Botton S,Bordessoule D,Tilly H,de Revel T,Bastard C,Preudhomme C,Michallet M,Fenaux P,Bastie JN,Socié G,Cordonnier C,Dombret H,Acute Leukemia French Association.

更新日期：2005-04-01 00:00:00

abstract：:Cyclosporine A (CsA) therapy based on 2-h concentrations (C2) after oral administration has demonstrated low acute rejection rates after solid organ transplantation. We analysed the correlation between C2 and trough (C0) levels of oral CsA therapy in samples obtained twice in consecutive weeks from 58 patients during ...

journal_title：Bone marrow transplantation

authors： Barkholt L,Remberger M,Bodegård H,Ringdén O,Böttiger Y

更新日期：2007-10-01 00:00:00

abstract：:Five years after the diagnosis of Ph chromosome-positive chronic myeloid leukemia (CML) a 31-year-old patient developed malignant nephrosclerosis with renal failure. He then underwent an allogeneic unrelated BMT in first chronic phase CML. The preparative regimen consisted of fractionated total body irradiation (TBI) ...

journal_title：Bone marrow transplantation

authors： Bischoff ME,Blau W,Wagner T,Wagenmann W,Dörner O,Basara N,Fauser AA

更新日期：1998-09-01 00:00:00

abstract：:In this study, outcomes for 575 adult ALL patients aged ≥45 years who underwent first allo-SCT in CR were analyzed according to the type of conditioning regimen (myeloablative conditioning (MAC) for 369 patients vs reduced-intensity conditioning (RIC) for 206 patients). Patients in the RIC group were older (median age...

journal_title：Bone marrow transplantation

authors： Tanaka J,Kanamori H,Nishiwaki S,Ohashi K,Taniguchi S,Eto T,Nakamae H,Minagawa K,Miyamura K,Sakamaki H,Morishima Y,Kato K,Suzuki R,Nishimoto N,Oba K,Masauzi N

更新日期：2013-11-01 00:00:00

abstract：:IL-10 plays an important role in the control of immune reactions during systemic infection. Here, IL-10 serum levels were investigated in patients after BMT. The IL-10 levels correlated with the clinical course of the patients and with serum levels of C-reactive protein (CRP) and neopterin (NP). A total of 26 patients...

journal_title：Bone marrow transplantation

authors： Hempel L,Körholz D,Nussbaum P,Bönig H,Burdach S,Zintl F

更新日期：1997-09-01 00:00:00

abstract：:Reduced-intensity conditioning (RIC) hematopoietic SCT (HSCT) is a potentially curative therapeutic option for patients with advanced follicular lymphoma (FL), but disease relapse remains the most common cause of failure. Radioimmunoconjugates administered before RIC allo-HSCT may enhance cytoreduction and allow more ...

journal_title：Bone marrow transplantation

authors： Abou-Nassar KE,Stevenson KE,Antin JH,McDermott K,Ho VT,Cutler CS,LaCasce AS,Jacobsen ED,Fisher DC,Soiffer RJ,Alyea EP,Koreth J,Freedman AS

更新日期：2011-12-01 00:00:00

abstract：:Ocular problems are common in recipients of stem cell transplantation (SCT), but ptosis is rarely reported and investigated. Among 346 consecutive SCT recipients, severe bilateral ptosis was noticed or reported in six cases (five women and one man), all with acute graft-versus-host disease (aGVHD) and chronic graft-ve...

journal_title：Bone marrow transplantation

authors： Hon C,Mak W,Kwok AK,Au WY

更新日期：2004-09-01 00:00:00

abstract：:Three widely used viability assessments were compared: (1) membrane integrity of nucleated cells using trypan blue (TB) exclusion and a fluorometric membrane integrity assay (SYTO 13 and propidium iodide), (2) enumeration of viable CD34+ cells, and (3) clonogenic assay (granulocyte-macrophage colony-forming units, CFU...

journal_title：Bone marrow transplantation

authors： Yang H,Acker JP,Cabuhat M,McGann LE

更新日期：2003-11-01 00:00:00

abstract：:Fetus-to-fetus transplantation has been suggested for the treatment of hemoglobinopathies in utero. However, dissimilar results have to date been obtained by different groups. We describe a case in which fetus-to-fetus transplantation in HLA-identical twins was performed at the 19th week of gestation by infusion of 0....

journal_title：Bone marrow transplantation

authors： Orlandi F,Giambona A,Messana F,Marino M,Abate I,Calzolari R,Damiani F,Jakil C,Renda M,Dieli F,Buscemi F,Westgren M,Ringden O,Maggio A

更新日期：1996-09-01 00:00:00

abstract：:A patient with acute myeloid leukemia secondary to therapy of choriocarcinoma underwent T cell non-depleted allogeneic bone marrow transplantation from an unrelated donor in first untreated relapse. Persistent/relapsed leukemia 4 months after transplantation did not respond to cessation of cyclosporine. Due to logisti...

journal_title：Bone marrow transplantation

authors： Singhal S,Powles R,Treleaven J,Mehta J

更新日期：1997-06-01 00:00:00

abstract：:There have been encouraging reports of the use of recombinant tissue plasminogen activator (tPA) in established veno-occlusive disease (VOD). Haemodialysis has been considered a contraindication to this therapy in view of the potential haemostatic complications. We report a case of a woman who developed moderately sev...

journal_title：Bone marrow transplantation

authors： Simpson DR,Browett PJ,Doak PB,Palmer SJ

更新日期：1994-10-01 00:00:00

abstract：:We initiated a randomized study of amifostine (the organic thiophosphate formerly known as WR-2721) given to patients during myeloablative conditioning therapy for allogeneic bone marrow transplantation. Amifostine was given at a dose of 1000 mg/day of conditioning and was well tolerated if attention was given to seru...

journal_title：Bone marrow transplantation

authors： Hwang WY,Koh LP,Ng HJ,Tan PH,Chuah CT,Fook SC,Chow H,Tan KW,Wong C,Tan CH,Goh YT

更新日期：2004-07-01 00:00:00

abstract：:It remains unclear how specific innovations in allogeneic hematopoietic cell transplantation (HCT) attained over the past decades have contributed to improvement in transplantation outcomes. To address this question, we conducted a registry-based study of adults with acute myeloid leukemia in first or second complete ...

journal_title：Bone marrow transplantation

authors： Yanada M,Masuko M,Mori J,Aoki J,Mizuno S,Fukuda T,Kakihana K,Ozawa Y,Ota S,Kanamori H,Mori T,Nakamae H,Eto T,Shiratori S,Maeda T,Iwato K,Ichinohe T,Kanda Y,Tanaka J,Atsuta Y,Yano S

更新日期：2019-04-01 00:00:00